RGT-61159
RGT-61159 Phase 3 (planned, not yet registered)
Rgenta Therapeutics · Phase 3 · Not yet recruiting · Enrollment 150
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| RGT-61159 84 mg + best supportive care | biomarker-selected R/M ACC (about 150 total, 2:2:1) | 84 mg | ITT | placebo | n/r |
| RGT-61159 60 mg + best supportive care | biomarker-selected R/M ACC | 60 mg | ITT | placebo | n/r |
| Placebo + best supportive care | biomarker-selected R/M ACC | placebo | ITT | n/r | n/r |
No efficacy figure is in this file for this study.